| pubmed-article:17888666 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17888666 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:17888666 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:17888666 | lifeskim:mentions | umls-concept:C0268563 | lld:lifeskim |
| pubmed-article:17888666 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:17888666 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:17888666 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:17888666 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:17888666 | lifeskim:mentions | umls-concept:C1510438 | lld:lifeskim |
| pubmed-article:17888666 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:17888666 | pubmed:issue | 24 | lld:pubmed |
| pubmed-article:17888666 | pubmed:dateCreated | 2007-10-22 | lld:pubmed |
| pubmed-article:17888666 | pubmed:abstractText | Based on the structural analysis of fumitremorgin C (FTC), imidazoline and beta-carboline amino acid benzylester, 14 novel 2-substitutedtetracyclic derivatives of tetrahydrocarboline 4a-n were prepared. We demonstrated that the exposure of MES-SA/Dx5 cells to some of 4a-n resulted in significant reduction of resistance of the cells against doxorubicin. This reduced resistance was accompanied by lowering of IC(50) value to doxorubicin from 1.55+/-0.26 micromol/L to 0.33+/-0.05 micromol/L for 2-(2-butyl)-derivative 4c, to 1.03+/-0.22 micromol/L for 2-methyl-derivative 4d, to 0.46+/-0.04 micromol/L for 2-benzyl-derivative 4f, to 0.98+/-0.25 micromol/L for 2-indole-3-yl-methyl-derivative 4h, to 0.36+/-0.03 micromol/L for 2-benzyloxycarbonylmethyl-derivative 4i, to 0.77+/-0.08 micromol/L for 2-benzyloxycarbonylethyl-derivative 4j, and to 0.77+/-0.08 micromol/L for 2-benzyloxycarbonylamino-n-butyl-derivative 4l. Proliferation assays of 4a-n indicated 4c,f,i,j were able to inhibit the proliferation of doxorubicin resistant MES-SA/Dx5 cells. The SAR analysis revealed that the benzylester form and the tetracyclic structure of 4a-n were critical for both sensitizing doxorubicin and the cellular anti-proliferative effect. | lld:pubmed |
| pubmed-article:17888666 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17888666 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888666 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17888666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888666 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888666 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17888666 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:17888666 | pubmed:issn | 1464-3391 | lld:pubmed |
| pubmed-article:17888666 | pubmed:author | pubmed-author:ZhaoMingM | lld:pubmed |
| pubmed-article:17888666 | pubmed:author | pubmed-author:PengShiqiS | lld:pubmed |
| pubmed-article:17888666 | pubmed:author | pubmed-author:JuJingfangJ | lld:pubmed |
| pubmed-article:17888666 | pubmed:author | pubmed-author:CuiGuohuiG | lld:pubmed |
| pubmed-article:17888666 | pubmed:author | pubmed-author:LiuJiawangJ | lld:pubmed |
| pubmed-article:17888666 | pubmed:author | pubmed-author:CuiChunyingC | lld:pubmed |
| pubmed-article:17888666 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17888666 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17888666 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:17888666 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17888666 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17888666 | pubmed:pagination | 7773-88 | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:meshHeading | pubmed-meshheading:17888666... | lld:pubmed |
| pubmed-article:17888666 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17888666 | pubmed:articleTitle | Dual-acting agents that possess reversing resistance and anticancer activities: Design, synthesis, MES-SA/Dx5 cell assay, and SAR of Benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo[3',4':1,2]pyridin[3,4-b]indol-2-substitutedacetates. | lld:pubmed |
| pubmed-article:17888666 | pubmed:affiliation | College of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, PR China. | lld:pubmed |
| pubmed-article:17888666 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17888666 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17888666 | lld:chembl |
